DHT, Follicle Miniaturization, and the Growth Cycle, Explained Without the Noise

The internet will tell you hair loss is about DHT. That's correct but incomplete, and the gap between those two things is where most people make the wrong decisions about treatment.

To understand what's actually happening, you need to understand the cycle first.

The growth cycle is a clock, not a switch

Every hair follicle on your scalp operates independently on a three-phase cycle. Anagen, the active growth phase, can last anywhere from two to seven years. This is when the hair shaft is being built, when cells in the hair bulb are dividing rapidly, when your hair is at its thickest and structurally strongest. During this phase, a dense capillary network surrounds the follicle, delivering oxygen, amino acids, and growth signals directly to the dermal papilla, the command center at the follicle's base.

After anagen ends, the follicle enters catagen, a two to three week transition in which growth stops, the follicle shrinks to roughly one-sixth of its normal size, and the hair shaft detaches from its blood supply. Then telogen: a two to four month resting period where the old hair sits dormant before eventually shedding and the cycle restarts.

In a healthy scalp, roughly 85 to 90 percent of follicles are in anagen at any given time. The ratio of active to resting follicles, the anagen-to-telogen ratio, is one of the most direct indicators of scalp health.

Where DHT enters the picture

Dihydrotestosterone is a derivative of testosterone, converted by the enzyme 5-alpha-reductase. In genetically susceptible follicles, typically concentrated at the frontal hairline and crown, DHT binds to androgen receptors in the dermal papilla and triggers a cascade of gene expression changes that directly shorten the anagen phase.

A follicle that once spent five years in active growth might be compressed, over successive cycles, to months. Then weeks. The hairs it produces don't disappear overnight, they progressively miniaturize. Terminal hairs, thick and pigmented, are gradually replaced by vellus hairs: fine, short, almost colorless strands. The follicle is still alive. It's just no longer functioning at full capacity.

This is why hair loss looks like thinning long before it looks like baldness. The follicle is in decline, not yet gone.

Research published in MDPI's International Journal of Molecular Sciences describes this process precisely: DHT binding to the androgen receptor in the dermal papilla leads to direct miniaturization of the hair follicle through disrupted signaling between the papilla and the surrounding hair matrix cells. In advanced androgenetic alopecia, the anagen-to-telogen ratio can drop from a normal 12:1 to as low as 5:1, or in severely affected areas, closer to 1:1.

The window that most people miss

Here's the part that rarely gets communicated clearly: follicle miniaturization is a gradual process. For most people, there is a window, often years wide, where the follicle is compromised but not irreversibly so. It's producing weaker hair. It's spending less time in anagen. But the infrastructure is still intact.

That window is where intervention matters most. Not after the follicle has been dormant for years. Not after the capillary network has fully receded. During the miniaturization process itself, when the follicle is still cycling, still responsive, still capable of producing a stronger hair if given the right environment.

The reason this window gets missed is that early miniaturization is subtle. Hair doesn't fall out dramatically. It gets finer. Parts get wider. Density shifts. By the time most people notice and start researching, they've already been in the window for a while, which means the urgency is real, but so is the opportunity.

What "treatment-grade" actually means at this level

Any serious approach to density loss has to operate on at least two fronts simultaneously. First, the hormonal and inflammatory environment at the follicle, addressing the signals that are shortening the anagen phase. Second, the vascular infrastructure, ensuring the dermal papilla has adequate supply to respond to those signals correctly.

A protocol that addresses only one front will produce partial results at best. Improving circulation to a follicle that's still being miniaturized by DHT-driven signaling won't restore full density. And attempting to shift the hormonal environment without supporting the vascular infrastructure means the follicle may not have the resources to actually re-enter anagen even if the signal is right.

This is why the conversation around hair loss protocol needs to be multi-mechanism by design, not because more is always better, but because the biology of miniaturization requires it.

Start early. Work at the follicle level. Understand what phase you're in.

That's the protocol.